It's quite possible for the new year to fulfill this ambitious name. Investing $122,100 in these three high-yield dividend ...
This makes Pfizer a potentially cheap stock to buy while collecting a solid dividend. It's generated about $14 billion in ...
Trading at a bit under $25 apiece, Pfizer 's (NYSE: PFE) shares appear tentatively cheap. However, the pharmaceutical giant reached these levels because it has faced significant headwinds, resulting ...
Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...
Given the stock's less-than favorable performance during the last few years as it emerged from its pandemic growth days and ...
Income investors have liked Pfizer (NYSE: PFE) for years. However, the big drugmaker's exceptionally juicy dividend these days has made its stock even more attractive. But when a dividend yield ...
Jim Cramer has built a strong reputation in the industry. He’s the Mad Money host who carefully picks growth stocks that have ...
At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. However, given the strong EPS headwinds and large EPS uncertainties, I suggest investors focus on other profit ...
Pfizer’s commitment to returning capital to shareholders is evident in its current annual dividend of $1.72 per share. This translates to a quarterly payment of $0.43 per share. As of May 22, 2025, ...
We regret to report that long term Pfizer Inc. (NYSE:PFE) shareholders have had that experience, with the share price ...
Pfizer's 7.45% forward dividend yield is misleading, as the share price decline outpaces the payout. Weak dividend growth, stagnant EPS projections, and a looming patent cliff are significant bearish ...
A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income-seeking investors. Such a substantial return often signals a ...